Brunella Napolitano

Medical Oncologist at @AOUCareggi and basket trial FFI at @GustaveRoussy

#lungcancer 🫁

[Jordi Remon @JordiRemon]

Adagrasib 600 mg BID in 2nd line is feasible for older patients
(>70years) in KRAS G12C NSCLC but not for pts withPS2. In this population, 30% of ttx discont for AEs. Could lower doses (400 mg BID) reach primary endpoint in population? Doses of inhibitors matter! #ELCC26

[Martina Gasparro @maarggi1]

Closing (temporarily) an unforgettable chapter at Gustave Roussy. Thank you to all the incredible people, from the chefs to my co-interns, who made this journey so special. Merci Paris, à très bientôt 🇫🇷 @dplanchard @JordiRemon @BenjaminBesseMD @LeQuartzy @brunella43665

[Brunella Napolitano @brunella43665]

@dplanchard @GustaveRoussy @maarggi1 Merci Professeur, et merci à tous ❤️

[d.planchard @dplanchard]

The @GustaveRoussy Thoracic Oncology 031 dream team (France, Canada, Italy…) is leaving after 6–12mo of sharing, happiness, and invaluable support in both clinical work and research.
We wish our amazing Fellows all the best in their future endeavors and see you soon! @maarggi1

[Roberto Ferrara @RobertoFerrara_]

EORTC Lung Cancer Group community at #ESMO25.
Young and Early Career Investigator connecting beyond institutions, countries and generations are the energy, innovation and the voice that keeps this community grow
@MOcchipintiMD @JcbenitezMD @M_Tagliamento @ACortelliniMD

[Jordi Remon @JordiRemon]

Zipalertinib in EGFRex20ins NSCLC reported 31% of intracranial ORR 🧠. Today crowded space of TKI for EGFRex20ins. New SoC? Best sequence? Brain activity and toxicity relevant for 1st Line decision. #ESMO25

[giovanni farinea @FarineaGiovanni]

Proud to present my poster on #osimertinib efficacy in advanced #NSCLCs harbouring uncommon #EGFR mutations: analysis form Italian biomarker #ATLAS database 🇮🇹 🎯. @myESMO #esmo2025 @pbyronz @PassigliaFra #silvianovello